

CLINICALTRIALS.GOV | NCT06307626 | NCT06307613

If you or someone you know has been diagnosed with Thyroid Eye Disease (TED) and is interested in joining a clinical study, consider participating in the UplighTED Study. The study is evaluating an investigational study drug, administered once a week, for its efficacy, safety, and tolerability in TED.



To qualify for participation, you must have all of the following*:

- 1. Be at least 18 years of age
- 2. Be capable of providing signed informed consent and complying with protocol requirements
- 3. Have received a diagnosis of active, moderateto-severe TED associated with autoimmune thyroid disease (Graves' disease or Hashimoto's thyroiditis)
- Have active symptoms such as redness, swelling, or pain of the eye or around the eye in the last 12 months, or recent worsening of the eye bulge
- 5. Have hyperthyroidism or thyroid disease that is considered under control

*Additional eligibility criteria can be found on the study website.

About the Study

In this study, the study drug is delivered through a pre-filled syringe which can be self-injected or injected by a caregiver just under the skin weekly. Although, you will need to attend all scheduled visits, you may ask for a home nurse to help you with weekly administration of study drug at home.

The main goals of this study are to learn about the effect of the investigational study drug compared with placebo on eye symptoms, quality of life, and about the safety of the investigational study drug in adult participants with TED.

Interested to Learn If This Study May Be an Option for You?

Please share this sheet with your physician and invite him/her to **scan the QR code** to visit the physician-facing study website to determine if it may be a good fit for you.

Physicians, scan to learn more



Patients who would like more information can visit UplightedstudyUS.com.

Sources

1. https://clinicaltrials.gov/study/NCT06307613; https://clinicaltrials.gov/study/NCT06307626

